Kazia Therapeutics Limited. (KZIA)

13.58 -19.64% (-3.32)

Over 5Y: -97.2%

2026-08-28
200 400 600
2021 2022 2023 2024 2025 2026

Financials Annual

2021 — Revenue: 15.2M 2021 — Operating Cash Flow: -9.1M 2021 — Net Income: -8.4M 2022 — Revenue: 0 2022 — Operating Cash Flow: -22.8M 2022 — Net Income: -25M 2023 — Revenue: 0 2023 — Operating Cash Flow: -15.2M 2023 — Net Income: -20.5M 2024 — Revenue: 2.3M 2024 — Operating Cash Flow: -9.6M 2024 — Net Income: -26.8M 2025 — Revenue: 42K 2025 — Operating Cash Flow: -13.3M 2025 — Net Income: -20.7M -18M -9M 0 9M 18M
2021 2022 2023 2024 2025
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-06-30, reported in AUD. The newest fact in the filings is dated 2025-12-31, 242 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.5
Accruals -10.4%
Asset turnover 0.00059×
ROA -29.1%
ROE -44.6%
Capex / sales —
EBITDA margin —
FCF margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
ROCE —
ROIC —
SBC / sales —

0 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

8.3
ND/EBITDA —
Cash runway 5.2 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 2.9×
Cash / Debt —
F-score —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales/sh Y/Y -99.1%
Shares change +107.9%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.